Considering both efficacy and side effects, Ubrogepant is effective for immediate symptom management with known, manageable side effects at recommended doses. Atogepant would appeal to those requiring prophylactic treatment, with efficacy and side effects assessed over longer-term usage. Given these points, choosing between the two should be tailored to the treatment intent (acute vs. preventive) and the patient’s health profile.
Browse Pharma
2 nov. 2023
Both Ubrogepant and Atogepant are effective treatments for migraine, functioning through the CGRP pathway. However, their targets and indications vary slightly, influencing their overall efficacy:
Ubrogepant: Proven effective for the acute treatment of migraine in adults. Studies demonstrated significant improvement in pain freedom and most bothersome symptom (MBS) freedom at 2 hours post-dose compared to placebo. The responder rates for pain freedom at 2 hours ranged from 19.2% to 21.8% across doses and studies.
Atogepant: Primarily used for the preventive treatment of migraine, indicating its use over a more extended period rather than immediate relief. This background suggests a broader application in preventing migraine episodes rather than the rapid alleviation seen with Ubrogepant.
Considering side effects, each medication presents unique profiles that might affect their suitability depending on the patient:
Ubrogepant Side Effects:
Common reactions include nausea (2-4%), somnolence (1-3%), and dry mouth (less than 2%).
Severe reactions such as hypersensitivity, including anaphylaxis and rash, have been noted in postmarketing experiences.
Atogepant Side Effects:
Clinical trials for Atogepant have not reported specific side effects in detail similar to Ubrogepant in the available context. However, given its preventive nature, the long-term side effects could be more relevant but are not highlighted.
Efficacy: Ubrogepant shows excellent efficacy for immediate relief from migraine symptoms, suited for acute treatment. Atogepant, while not directly comparable because it's used preventively, helps reduce the frequency of migraine attacks over a longer period.
Side Effects: Ubrogepant has a relatively low but definite side effect profile and specific severe hypersensitivity reactions. Atogepant’s side effects are less detailed in the provided material, indicating the need for further specific comparative studies.
Considering both efficacy and side effects, Ubrogepant is effective for immediate symptom management with known, manageable side effects at recommended doses. Atogepant would appeal to those requiring prophylactic treatment, with efficacy and side effects assessed over longer-term usage. Given these points, choosing between the two should be tailored to the treatment intent (acute vs. preventive) and the patient’s health profile.
Approval Date: June 6, 2024 Trade Name (Generic Name): Rytelo™ (imetelstat) Approved For: Treatment of adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent...
6 juin 2024
The U.S. FDA granted accelerated approval for Iqirvo as a first-in-class PPAR treatment for primary biliary cholangitis. Iqirvo is the first new medicine approved in nearly a decade for this rare liver...
11 juin 2024
The FDA Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that donanemab shows clinical benefit for the treatment of early Alzheimer's disease. - If approved, donanemab would become the second disease-modifying drug for Alzheimer's to receive full approval, expanding the arsenal of available drugs needed to treat Alzheimer's with combination therapy.
10 juin 2024
Pierre Fabre Laboratories announce granting of European marketing authorization for OBGEMSA™ (vibegr
The European Commission (EC) has granted marketing authorization for OBGEMSA™ (vibegron) by Pierre Fabre Laboratories, indicated for the symptomatic treatment of overactive bladder syndrome in adults,...
29 juin 2024
FDA Approves Rytelo (imetelstat) for the Treatment of Adult Patients with Lower-Risk MDS with Transf
Approval Date: June 6, 2024 Trade Name (Generic Name): Rytelo™ (imetelstat) Approved For: Treatment of adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent...
6 juin 2024
the U.S. Food and Drug Administration (FDA) granted approval for Yesafili (aflibercept-jbvf), an interchangeable biosimilar to Eylea (aflibercept). Aflibercept products function by inhibiting vascular endothelial growth factor (VEGF), which hinders abnormal blood vessel growth in the eye. By blocking VEGF, these products can slow down or reduce damage to the retina and help preserve vision
23 mai 2024
Considering both efficacy and side effects, Ubrogepant is effective for immediate symptom management with known, manageable side effects at recommended doses. Atogepant would appeal to those requiring prophylactic treatment, with efficacy and side effects assessed over longer-term usage. Given these points, choosing between the two should be tailored to the treatment intent (acute vs. preventive) and the patient’s health profile.
2 nov. 2023
